These results elucidate the mechanism by which DDX5 orchestrates NRF2 activation in vivo and underscore the therapeutic potential of siRNA-mediated therapies targeting NRF2 in combination with sorafenib for the effective treatment of HCC. The gene discussed is DDX5; the disease is hepatocellular carcinoma.